Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Fosinopril
Drug ID BADD_D00967
Description Fosinopril is a phosphinic acid-containing ester prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly hydrolyzed to fosinoprilat, its principle active metabolite. Fosinoprilat inhibits ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Fosinopril may be used to treat mild to moderate hypertension, as an adjunct in the treatment of congestive heart failure, and to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy.
Indications and Usage For treating mild to moderate hypertension, use as an adjunct in treating congestive heart failure, and may be used to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy.
Marketing Status approved
ATC Code C09AA09
DrugBank ID DB00492
KEGG ID D07992
MeSH ID D017328
PubChem ID 3420
TTD Drug ID D0X8KY
NDC Product Code 68788-7717; 69097-857; 71335-0187; 69097-856; 50090-2977; 69097-858; 71335-0381
UNII R43D2573WO
Synonyms Fosinopril | Fosenopril | Fosinil | Fositens | Fosinopril Sodium | Sodium, Fosinopril | Fosinopril, (1(S*(R*)),2 alpha,4 beta)-Isomer | Fosinopril, (1(S*(R*)),2 alpha,4 alpha)-(D-Pro)-Isomer | Tenso Stop | Tensocardil | Fozitec | Hiperlex | Monopril | Fosinorm | Newace | Staril | SQ-28,555 | SQ 28,555 | SQ28,555 | SQ-28555 | SQ 28555 | SQ28555 | Dynacil | Fosinopril, (1(S*(S*)),2 alpha,4 beta)-Isomer
Chemical Information
Molecular Formula C30H46NO7P
CAS Registry Number 98048-97-6
SMILES CCC(=O)OC(C(C)C)OP(=O)(CCCCC1=CC=CC=C1)CC(=O)N2CC(CC2C(=O)O)C3CCCCC3
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Vomiting07.01.07.003--
Weight decreased13.15.01.005--
Weight increased13.15.01.006--
Xanthopsia06.02.05.002--Not Available
Tubulointerstitial nephritis20.05.02.002--Not Available
Peripheral swelling08.01.03.053; 02.05.04.015--Not Available
Weight fluctuation14.03.02.002--Not Available
Red blood cell sedimentation rate increased13.01.03.001--Not Available
Musculoskeletal chest pain22.09.01.001; 15.03.04.012--
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Eschar24.04.03.024; 12.01.08.008; 23.03.03.027--Not Available
Skin induration23.03.03.020--
Respiratory tract congestion22.02.07.003--Not Available
Skin bacterial infection23.11.02.017; 11.02.01.007--Not Available
Protein urine present13.13.02.006--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Affect lability19.04.01.001--Not Available
Transaminases increased13.03.04.036--Not Available
Haemorrhage24.07.01.002--Not Available
Dermatologic examination abnormal13.15.01.019--Not Available
Serositis08.01.05.006--Not Available
Disturbance in sexual arousal19.08.04.003--Not Available
Blood alkaline phosphatase increased13.04.02.004--
Urine output increased13.13.03.002--Not Available
Antinuclear antibody positive13.06.01.003--Not Available
Hot flush21.02.02.001; 08.01.03.027; 24.03.01.005--
Appetite disorder19.09.01.002; 14.03.01.004--Not Available
Breast disorder21.05.04.004--Not Available
Cranial nerve disorder17.04.01.001--Not Available
Abnormal behaviour19.01.01.001--Not Available
The 8th Page    First    Pre   8 9    Next   Last    Total 9 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene